Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Peter G. Maslak x
Clear All Modify Search
Full access

Mark G. Frattini and Peter G. Maslak

Edited by Kerrin G. Robinson

Acute myeloid leukemia is a heterogeneous disease. Standard treatments may be applied to biologically distinct subgroups, resulting in different treatment outcomes. The concept of risk-adapted therapy allows for recognition of this biologic diversity by incorporating key biologic features, such as cytogenetic and molecular markers, when formulating treatment regimens and investigating emerging targeted therapies based on disease characteristics.